Shilpa Medicare Stock Screener | Share Price & Fundamental Analysis

SHILPAMED Pharmaceuticals
Screen Shilpa Medicare share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹318.15
▼ -0.15 (-0.05%)
2026-01-07 00:00:00
Share Price BSE
₹318.20
▲ 0.10 (0.03%)
2026-01-07 00:00:00
Market Cap ₹6,172.56 Cr.
P/B Ratio 2.57
EPS (TTM) ₹8.04
Dividend Yield 0.16%
Debt to Equity 0.36
52W High ₹847.75
52W Low ₹315.85
Operating Margin 29.00%
Profit Margin 11.83%
Revenue (TTM) ₹372.00
EBITDA ₹110.00
Net Income ₹44.00
Total Assets ₹3,311.00
Total Equity ₹2,364.00

Shilpa Medicare Share Price History - Stock Screener Chart

Screen SHILPAMED historical share price movements with interactive charts. Analyze price trends and patterns.

Shilpa Medicare Company Profile - Fundamental Screener

Screen Shilpa Medicare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SHILPAMED shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE790G01031

Shilpa Medicare Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen SHILPAMED balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Assets
Total Assets 3,311 3,093 2,904 2,876 2,632 1,989 1,610 1,499 1,472 931
Current Assets 986 877 770 887 903 624 545 672 730 354
Fixed Assets 1,418 1,385 1,368 1,342 1,111 650 558 534 492 393
Liabilities
Total Liabilities 3,311 3,093 2,904 2,876 2,632 1,989 1,610 1,499 1,472 931
Current Liabilities 273 600 345 453 561 257 167 154 251 67
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 2,364 1,800 1,774 1,811 1,468 1,322 1,190 1,080 984 642
Share Capital 10 9 9 9 8 8 8 8 8 8
Reserves & Surplus 2,363 1,800 1,775 1,814 1,471 1,321 1,189 1,077 979 632
Screen SHILPAMED income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec 2022-Sept 2022-Jun 2022-Mar
Revenue 372 328 341 321 349 302 300 289 315 262 266 266 267 269 346
Expenses 262 231 282 239 258 223 222 222 255 214 227 231 253 241 268
EBITDA 110 97 59 82 91 80 79 67 60 48 39 34 14 28 78
Operating Profit % 29.00% 28.00% 15.00% 25.00% 25.00% 24.00% 24.00% 23.00% 19.00% 18.00% 14.00% 12.00% 4.00% 8.00% 21.00%
Depreciation 30 29 29 29 28 27 27 27 28 27 26 24 23 22 22
Interest 16 19 15 12 26 24 24 26 23 18 18 18 14 10 9
Profit Before Tax 64 50 15 42 37 29 28 14 9 3 -4 -8 -22 -4 46
Tax 20 3 1 10 19 15 3 10 8 2 4 -1 -4 -6 17
Net Profit 44 47 15 32 18 14 25 5 2 1 -8 -7 -19 2 30
EPS 5.50 4.79 1.48 3.25 1.83 1.46 2.82 0.53 0.19 0.14 -0.93 -0.76 -2.15 0.10 3.40

Shilpa Medicare Cash Flow Screener - Liquidity Fundamentals

Screen SHILPAMED cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 132 137 180 105 47 124 147 45 38 129
Investing Activities -198 -171 -232 -286 -404 -290 -196 -10 -257 -106
Financing Activities 63 47 46 83 436 176 10 -61 313 -20
Net Cash Flow -3 13 -7 -98 79 10 -40 -26 93 3
Screen SHILPAMED shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Apr 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 44.23% 44.23% 44.23% 50.01% 44.39% 44.39% 44.33% 44.23%
FII Holding 10.97% 11.20% 10.92% 0.00% 0.00% 9.08% 9.58% 9.90%
DII Holding 7.55% 7.46% 7.67% 1.59% 6.13% 7.61% 8.18% 8.27%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 24.43% 23.21% 23.34% 27.64% 24.54% 24.69% 23.94% 24.40%
Other Holding 12.83% 13.90% 13.84% 20.75% 24.94% 14.23% 13.96% 13.21%
Shareholder Count 50,108 48,636 52,065 44,793 44,809 41,072 42,784 49,034

Shilpa Medicare Dividend Screener - Share Yield Analysis

Screen SHILPAMED dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹1.00 0.31%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹1.10 0.96%
2021-March ₹1.10 0.55%
2020-March ₹1.10 0.66%
2019-March ₹1.00 0.82%
2018-March ₹0.70 0.41%
2017-March ₹0.60 0.26%
2016-March ₹0.60 0.19%

Shilpa Medicare Index Membership - Market Screener Classification

Screen SHILPAMED by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.

Shilpa Medicare Market Events Screener - Corporate Actions

Screen SHILPAMED market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 1.00 /share 5.73%
Dividend ₹ 1.10 /share -10.81%
Annual General Meeting NA 26.59%
Dividend ₹ 1.10 /share 7.43%
Annual General Meeting NA -53.04%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 11.79%
2025-10-03 2025-10-03 Bonus 1:1 -5.18%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 2.33%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 10.39%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 5.08%
2024-11-13 2024-11-13 Quarterly Result Announcement NA 3.95%

Shilpa Medicare Competitors Screener - Peer Comparison

Screen SHILPAMED competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,734 39.30 54,729 9.71% 10,980 39.06
Divis Laboratories 168,851 68.25 9,712 18.67% 2,191 44.96
Torrent Pharmaceuticals 129,357 59.98 11,539 6.99% 1,911 59.35
Cipla 120,557 22.21 28,410 7.12% 5,291 42.76
Dr Reddys Laboratories 105,645 18.46 33,741 16.73% 5,725 49.97
Lupin 95,023 21.85 22,910 13.74% 3,306 50.10
Zydus Life Science 90,707 18.09 23,511 18.55% 4,615 34.06
Mankind Pharma 88,846 50.78 12,744 20.90% 2,007 40.67
Aurobindo Pharma 68,901 20.36 32,346 9.43% 3,484 46.33
Alkem Laboratories 65,390 27.28 13,458 3.70% 2,216 37.45

Shilpa Medicare Company Announcements - News Screener

Screen SHILPAMED latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-07 Ex-Parte Ad-Interim Injunction Order Regarding Pharmaceutical Drug Product Containing Ruxolitinib And/Or Ruxolitinib Salts API View
2026-01-03 Closure of Trading Window View
2025-12-12 Intimation Under Of Regulation 30 Of The SEBI(LODR) Regulations View
2025-11-22 USFDA Inspection Of Shilpa Medicare Ltd. Unit IV Jadcherla Telangana View
2025-11-19 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2025-11-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2025-11-17 Announcement Under Regulation 30 Of The SEBI(LODR) Regulations. View
2025-11-13 Announcement under Regulation 30 (LODR)-Investor Presentation View
2025-11-13 Announcement under Regulation 30 (LODR)-Meeting Updates View
2025-11-13 Outcome Of The Board Meeting Of The Company Held On 13 November 2025 View
2025-11-13 Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 13 November 2025 View
2025-11-11 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-11-10 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot View
2025-11-10 Announcement Under Regulation 30 Of The SEBI(LODR) Regulations 2015 View
2025-11-10 Announcement Under Regulation 30 Of The SEBI(LODR) Regulations 2015 View
2025-11-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2025-11-05 Board Meeting Intimation for Consider And Approve Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2025 View
2025-10-27 Announcement Under Regulation 30 & 30(A) Of The SEBI (LODR) Regulations 2015 View
2025-10-16 Intimation Under Regulation 30 Read With Regulation 30A And Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) View
2025-10-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View